血必净通过miR-155/JAK2/STAT1信号通路对肺炎克雷伯菌所致重症肺炎大鼠肺组织损伤的影响

doi:10.3969/j.issn.1006-5725.2023.18.009

Abstract

Abstract:

Objective To investigate the effect of Xuebijing on rats with severe pneumonia （SP） and its possible mechanism. Methods Forty SP rats were randomly divided into model group， miRNA-155 agonist group （miRNA-155 agonist， 80 mg/kg）， Xuebijing low-dose group （Xuebijing injection， 4 mg/kg）， Xuebijing high-dose group （Xuebijing injection， 8 mg/kg）， miR-155 agonist + Xuebijing group （miR-155 agonist 80 mg/kg， Xuebijing injection 8 mg/kg）， with 8 rats in each. Eight healthy rats were included into control group. Control group and model group were injected with the same amount of normal saline through caudal vein. After 7 days of continuous administration， lung coefficient （LI）， interleukin-1β （IL-1β） level， receptor tyrosine kinase 2 （JAK2）， signal transduction and transcriptional activator 1 （STAT1） protein expression were detected in each group. Results Compared with those in the model group， the level of LI and IL-1β， p-JAK2/JAK2 and p-STAT1/STAT1 in lung tissue were increased in miR-155 agonist group （P < 0.05）. The level of LI and IL-1β， P-JAK2 /JAK2 and P-Stat1/STAT1 in lung tissue were decreased in low and high dose Xuebijing group and miR-155 agonist + Xuebijing group （P < 0.05）. Compared with those in miR-155 agonist group， the level of LI and IL-1β， P-JAK2 /JAK2 and P-Stat1/STAT1 in lung tissue were decreased in Xuebijing low and high dose group， and miR-155 agonist + Xuebijing group （P < 0.05）. Compared with those in Xuebijing low dose group， the level of LI， IL-1β， p-JAK2/JAK2 and p-STAT1/STAT1 in lung tissue were increased in Xuebijing high dose group （P < 0.05）. Compared with those in Xuebijing group， LI and IL-1β level， P-JAK2 /JAK2 and P-Stat1 /STAT1 in lung tissue were increased in miR-155 agonist + Xuebijing group （P < 0.05）. Conclusion Xuebijing can reduce lung injury in SP rats， possibly by inhibiting the expression of miR-155 and thereby reducing the JAK2/STAT1 signaling pathway.

Key words: Xuebijing, microRNA-155, klebsiella pneumoniae, severe pneumonia

CLC Number:

R563.1

Fei WEI,Xiangyu WANG,Zhiyong LIU. Effect of Xuebijing on lung tissue damage induced by Klebsiella pneumoniae in rats with severe pneumonia through miR⁃155/JAK2/STAT1 signaling pathway[J]. The Journal of Practical Medicine, 2023, 39(18): 2335-2341.

Figures/Tables 9

Tab.1

Tab.2

Fig.1

Tab.3

Fig.2

Tab.4

Tab.5

Tab.6

Fig.3

References 26

1	WANG G， ZHAO G， CHAO X， et al. The Characteristic of Virulence， Biofilm and Antibiotic Resistance of Klebsiella pneumoniae［J］. Int J Environ Res Public Health，2020，17（17）：6278.
2	WALKER K A， MINER T A， PALACIOS M， et al. A Klebsiella pneumoniae Regulatory Mutant Has Reduced Capsule Expression but Retains Hypermucoviscosity［J］. mBio，2019，10（2）：82.
3	ZHANG P， SHI Q， HU H， et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China［J］. Clin Microbiol Infect，2020，26（1）：121-124.
4	徐朝军，刘丹薇，李开瑞，等. 从调控miR-17-5p表达探讨血必净注射液对大鼠体外循环急性肺损伤的防治作用及机制［J］. 中华危重病急救医学，2019，31（7）：867-872.
5	WANG H F， LI Y， WANG Y Q， et al. MicroRNA-494-3p alleviates inflammatory response in sepsis by targeting TLR6［J］. Eur Rev Med Pharmacol Sci，2019，23（7）：2971-2977.
6	JIANG K， YANG J， GUO S， et al. Peripheral Circulating Exosome-Mediated Delivery of miR-155as a Novel Mechanism for Acute Lung Inflammation［J］. Mol Ther，2019，27（10）：1758-1771.
7	吴萍，何文龙，付云，等. 秦皮甙对重症肺炎大鼠炎症因子表达及相关通路活化的影响［J］. 免疫学杂志，2020，36（4）：292-298.
8	卢伟波，赵子文，钟维农，等. 肺炎克雷伯杆菌致大鼠重症肺炎模型的改良与评估［J］. 中国病理生理杂志，2013，29（3）：571-576.
9	熊远珍. 实验动物与人用药量的新换算［J］. 江西医学院学报，1997， 39（4）：41.
10	彭官清，凌乔，余舒莹. miRNA-155对重症肺炎大鼠肺组织的保护作用及机制［J］. 重庆医学，2019，48（17）：2890-2894.
11	安月鹏，杨素清，周妍妍. 基于miR-155调控SOCS1-JAK2/STAT3通路研究蜈蚣败毒饮治疗银屑病模型鼠的机制［J］. 中国皮肤性病学杂志，2021，35（4）：405-412.
12	孙颖，刘玲，施晓艳，等. 丹皮酚通过降低miR-155/JAK1-STAT1通过抑制巨噬细胞M1极化［J］. 中国中药杂志，2020，45（9）：2158-2164.
13	SONG Y， YAO C， YAO Y， et al. XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia： A Randomized Controlled Trial［J］. Crit Care Med，2019，47（9）：735-743.
14	张国荣，刘楠，刘莉. 肺炎克雷伯菌肺炎对小鼠NLRP3 炎症通路的影响［J］. 世界临床药物，2019，40（2）：95-100.
15	蔡勇，黄楚鑫，周蕾，等. 广州8313例社区获得性肺炎住院儿童人偏肺病毒流行病学特点［J］. 实用医学杂志， 2019， 35（19）：3094-3097.
16	WANG J， ZHU J， GUO J， et al. Could Xuebijing Injection Reduce the Mortality of Severe Pneumonia Patients A Systematic Review and Meta-Analysis［J］. Evid Based Complement Alternat Med，2020，20（20）：9605793.
17	QUERO L， TIADEN A N， HANSER E， et al. miR-221-3p Drives the Shift of M2-Macrophages to a Pro-Inflammatory Function by Suppressing JAK3/STAT3 Activation［J］. Front Immunol，2019，27（10）：3087.
18	KALKUSOVA K， TABORSKA P， STAKHEEV D， et al. The Role of miR-155 in Antitumor Immunity［J］. Cancers （Basel）， 2022， 14（21）：5414.
19	XIAO Q. Cinnamaldehyde attenuates kidney senescence and injury through PI3K/Akt pathway-mediated autophagy via downregulating miR-155［J］. Ren Fail， 2022， 44（1）：601-614.
20	LI T， QIAN Y， MIAO Z， et al. Xuebijing Injection Alleviates Pam3CSK4-Induced Inflammatory Response and Protects Mice From Sepsis Caused by Methicillin-Resistant Staphylococcus aureus［J］. Front Pharmacol，2020，21（11）：104.
21	XIE S， YAN P， YAO C， et al. Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease： study protocol for a randomized controlled trial［J］. Trials，2019，20（1）：136.
22	HE Y， LI Q， ZHOU W， et al. Coniferyl aldehyde alleviates LPS-induced WI-38 cell apoptosis and inflammation injury via JAK2-STAT1 pathway in acute pneumonia［J］. Allergol Immunopathol （Madr）， 2021，49（5）：72-77.
23	CHEN R， WANG J， DAI X， et al. Augmented PFKFB3-mediated glycolysis by interferon-γ promotes inflammatory M1 polarization through the JAK2/STAT1 pathway in local vascular inflammation in Takayasu arteritis［J］. Arthritis Res Ther，2022，24（1）：266.
24	吴舒懋，苏培媛，陈玲，等. mir-34a/sirt1在肺炎克雷伯菌所致重症肺炎大鼠中的表达［J］. 中国医学装备，2021，18（2）：149-155.
25	吴程程，娄成龙，韩淑萍. 血必净注射液通过调控p38 MAPK/NF-KB通路对百草枯中毒大鼠急性肺损伤保护作用的研究［J］. 中国中医急症，2019，28（5）：819-822，844.
26	YE Y， AN Y， WANG M， et al. Expression of Carboxypeptidase X M14 Family Member 2 Accelerates the Progression of Hepatocellular Carcinoma via Regulation of the gp130/JAK2/Stat1 Pathway［J］. Cancer Manag Res，2020，3（12）：2353-2364.

基因	引物序列
miR-155	Forward：5′-CGGCGGTTAATGCTAATTGTGAT-3′
miR-155	Reverse：5′-ATCTTTTTCCAACATCCAT-3′
U6	Forward：5′-TCCGATCGTGAAGCGTTC-3′
U6	Reverse：5′-GTGCAGGGTCCGAGGT-3′

基因	引物序列
JAK2	Forward：5′-TTCTGTGGCCTCAGATGTGTG-3′
JAK2	Reverse：5′-TGAAAGAGGGACGTTGGTTGA-3′
STAT1	Forward：5′-ATTTCTCCTTCTGGCCTTG-3′
STAT1	Reverse：5′-AGGAACGTCCCTGGCTG-3′
GAPDH	Forward：5′-TGCACCACCAACTGCTTAGC-3′
GAPDH	Reverse：5′-GCATGGACTGTGGTCATGAG-3′

组别	鼠量	IL-1β	IL-18	TNF-α
对照组	8	52.83 ± 6.12	92.34 ± 8.38	66.53 ± 5.22
模型组	8	87.48 ± 8.24^a	238.87 ± 10.54^a	102.31 ± 7.34^a
miR-155激动剂组	8	96.38 ± 9.24^ab	253.15 ± 12.06^ab	118.28 ± 9.26^ab
血必净低剂量组	8	80.31 ± 8.35^abc	172.38 ± 7.49^abc	84.68 ± 7.08^abc
血必净高剂量组	8	66.23 ± 6.03^abcd	113.23 ± 10.03^abcd	75.85 ± 6.82^abcd
miR-155激动剂+血必净组	8	79.77 ± 8.05^abde	168.77 ± 9.05^abde	83.71 ± 7.25^abde

组别	鼠量	miR-155
对照组	8	1.00 ± 0.02
模型组	8	3.29 ± 0.72^a
miR-155激动剂组	8	3.72 ± 0.82^ab
血必净低剂量组	8	2.63 ± 0.61^abc
血必净高剂量组	8	1.90 ± 0.55^abcd
miR-155激动剂+血必净组	8	2.60 ± 0.60^abce

组别	鼠量	JAK2 mRNA	STAT1 mRNA
对照组	8	1.00 ± 0.05	1.00 ± 0.03
模型组	8	2.89 ± 0.96^a	3.31 ± 1.26^a
miR-155激动剂组	8	3.27 ± 1.01^ab	4.07 ± 1.68^ab
血必净低剂量组	8	1.88 ± 0.44^abc	2.98 ± 0.43^abc
血必净高剂量组	8	1.31 ± 0.24^abcd	2.27 ± 0.77^abcd
miR-155激动剂+血必净组	8	1.90 ± 0.40^abde	3.02 ± 0.48^abde

Effect of Xuebijing on lung tissue damage induced by Klebsiella pneumoniae in rats with severe pneumonia through miR⁃155/JAK2/STAT1 signaling pathway

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 9

References 26

Related Articles 9

Recommended Articles

Metrics

Comments

组别	鼠量	p-JAK2/JAK2	p-STAT1/STAT1
对照组	4	0.24 ± 0.02	0.31 ± 0.03
模型组	4	0.48 ± 0.04^a	0.58 ± 0.03^a
miR-155激动剂组	4	0.83 ± 0.03^ab	0.81 ± 0.02^ab
血必净低剂量组	4	0.26 ± 0.04^abcd	0.41 ± 0.04^abc
血必净高剂量组	4	0.21 ± 0.03^abcd	0.29 ± 0.04^abcd
miR-155激动剂+血必净组	4	0.28 ± 0.04^abde	0.43 ± 0.04^abde

[1]	Jingcai WANG,Chunyan GUO,Lixin YANG,Xiaoqing. JING. Correlation of serum RAGE and HMGB1 expression with the occurrence of acute respiratory distress syndrome and IFN⁃γ/IL⁃4 ratio in patients with severe pneumonia [J]. The Journal of Practical Medicine, 2024, 40(4): 515-520.
[2]	HE Dehua, LIU Ming, CHEN Qimin, LIU Xu.. Application of metagenomic next⁃generation sequencing in the etiological detection in patients with severe pneumonia [J]. The Journal of Practical Medicine, 2023, 39(8): 948-952.
[3]	Xingle YANG,Tingting XIA,Chunlei ZUO,Jiaxin. SHI. Value of microbiology rapid on⁃site evaluation in severe pneumonia [J]. The Journal of Practical Medicine, 2023, 39(22): 2964-2968.
[4]	JIANG Jiali, CHEN Ting, TONG Wenjia, DING Jie, XU Weihua. . Expression and clinical significance of PI3K and MMP⁃9 in bronchoscopic alveolar lavage fluid of children with severe pneumonia in PICU [J]. The Journal of Practical Medicine, 2023, 39(15): 1939-1944.
[5]	WU Daorong, YAN Xuebo, WEN Tingyu, SONG Qiuming. . The evaluation value of serum and lower respiratory tract secretion SLPI in severe pneumonia in ICU [J]. The Journal of Practical Medicine, 2023, 39(12): 1529-1535.
[6]	ZHANG Chunling, YANG Yuanjian, LIU Chang, ZHANG Weihua.. Clinical significance of serum PCT，BBP，IL⁃6 combined SOFA score in prognosis assessment of patients with severe pneumonia [J]. The Journal of Practical Medicine, 2022, 38(2): 168-172.
[7]	LIANG Wenmei, FU Bao, ZHAO Xiaoyu, SU De, DAI Dahua, GONG Minmin, FU Xiaoyun. . Effects of Xuebijing Injection combined with low molecular weight heparin on PTX3 and HPSE levels in elderly patients with acute respiratory distress syndrome [J]. The Journal of Practical Medicine, 2022, 38(14): 1814-1818.
[8]	XIE Hui, FENG Jun, HUANG Qiujie, WANG Junyi, YE Wen.. Effects of ulinastatin combined with Shenmai Injection on myocardial injury protection and pulmonary function in patients with severe pneumonia [J]. The Journal of Practical Medicine, 2022, 38(10): 1260-1264.
[9]	HE Jun, WU Songbai, LYU Ailian, DAI Yao, HUANG Kang, FANG Xiang, LYU Jianlei, LIU Min, ZHANG Quan, PENG Jing. Research on strategy of immunotherapy in elderly sepsis patients with immunosuppression [J]. The Journal of Practical Medicine, 2021, 37(6): 718-721.